Acutus Medical (AFIB)

Company Profile

Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Company profile

Ticker

AFIB

Exchange

NASDAQ

Website

www.acutusmedical.com

CEO

Vince Burgess

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Surgical and Medical Instrument Manufacturing

Industry (SIC)

Surgical & Medical Instruments & Apparatus

3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...

SEC CIK

0001522860

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Acutus Medical, N.V. • Acutus Medical UK Limited ...

IRS number

451306615

AFIB stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

9 Jan 23

EFFECT

Notice of effectiveness

22 Dec 22

424B5

Prospectus supplement for primary offering

21 Dec 22

CORRESP

Correspondence with SEC

9 Dec 22

Entry into a Material Definitive Agreement

10 Nov 22

Acutus Medical Reports Third Quarter 2022 Financial Results

10 Nov 22

Transcripts

View all

AFIB

Earnings call transcript

2022 Q3

13 Nov 22

AFIB

Earnings call transcript

2022 Q2

12 Aug 22

AFIB

Earnings call transcript

2022 Q2

13 May 22

AFIB

Earnings call transcript

2021 Q4

31 Mar 22

AFIB

Earnings call transcript

2021 Q3

12 Nov 21

AFIB

Earnings call transcript

2021 Q2

13 Aug 21

AFIB

Earnings call transcript

2021 Q1

13 May 21

AFIB

Earnings call transcript

2020 Q2

18 Sep 20

Latest ownership filings

View all

Financial summary

Financial statements Chart AFIB financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	32.15 mm	32.15 mm	32.15 mm	32.15 mm	32.15 mm	32.15 mm
Cash burn (monthly)	6.19 mm	2.21 mm	6.82 mm	6.40 mm	7.95 mm	7.89 mm
Cash used (since last report)	26.61 mm	9.49 mm	29.33 mm	27.53 mm	34.17 mm	33.92 mm
Cash remaining	5.54 mm	22.66 mm	2.82 mm	4.62 mm	-2.02 mm	-1.76 mm
Runway (months of cash)	0.9	10.3	0.4	0.7	-0.3	-0.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

AFIB institutional ownership history Ownership history

79.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	40	50	-20.0%
Opened positions	7	11	-36.4%
Closed positions	17	29	-41.4%
Increased positions	9	11	-18.2%
Reduced positions	9	19	-52.6%

13F shares	Current	Prev Q	Change
Total value	58.97 mm	62.45 mm	-5.6%
Total shares	22.71 mm	23.61 mm	-3.8%
Total puts	27.10 k	27.40 k	-1.1%
Total calls	37.90 k	115.30 k	-67.1%
Total put/call ratio	0.7	0.2	+200.9%

Largest owners	Shares	Value	Change
Flynn James E	9.64 mm	$10.80 mm	0.0%
Deerfield Management	2.65 mm	$2.33 mm	+0.1%
Orbimed Advisors	2.65 mm	$2.33 mm	0.0%
Advent Life Sciences	1.62 mm	$5.51 mm	0.0%
Fares Zahir	1.17 mm	$33.61 mm	0.0%
Vanguard	1.14 mm	$1.01 mm	+70.1%
Capital World Investors	797.52 k	$702.00 k	-50.2%
Kamunting Street Capital Management	564.71 k	$497.00 k	-2.8%
Millennium Management	428.20 k	$377.00 k	+121.7%
Renaissance Technologies	402.70 k	$354.00 k	+53.9%

Largest transactions	Shares	Bought/sold	Change
Capital World Investors	797.52 k	-802.48 k	-50.2%
Vanguard	1.14 mm	+470.72 k	+70.1%
Millennium Management	428.20 k	+235.10 k	+121.7%
Gsa Capital Partners	137.41 k	-234.51 k	-63.1%
Clear Street	0.00	-180.00 k	EXIT
Aqr Capital Management	0.00	-174.35 k	EXIT
Renaissance Technologies	402.70 k	+141.10 k	+53.9%
MS Morgan Stanley	177.85 k	+112.08 k	+170.4%
Ergoteles	0.00	-93.90 k	EXIT
Sabby Management	0.00	-93.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AFIB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Feb 23	Takeo Mukai	FORM 4	Payment of exercise	Dispose F	No	No	1.87	2,855	5.34 k	36,448
1 Feb 23	David Roman	FORM 4	Payment of exercise	Dispose F	No	No	1.87	10,196	19.07 k	248,159
1 Feb 23	Charlie Piscitello	FORM 4	Payment of exercise	Dispose F	No	No	1.87	6,627	12.39 k	44,038
1 Feb 23	Tom Sohn	FORM 4	Payment of exercise	Dispose F	No	No	1.87	6,525	12.20 k	57,190
1 Feb 23	Kevin Mathews	FORM 4	Payment of exercise	Dispose F	No	No	1.87	3,540	6.62 k	24,153